Efficacy of Ofatumumab on Microglia in Patients with Relapsing forms of Multiple Sclerosis: Study Design

Tarun Singhal¹, Howard L Weiner¹, Tanuja Chitnis¹, Rohit Bakshi¹, Maria Houtchens¹, Bonnie Glanz¹, Kelsey O'Connor¹, John Hunter Ficke¹, Éero Rissanen¹, Jon Zurawski¹, Steven Cicero¹, Harald Kropshofer², Nicholas Seneca², Brandon Brown³, Marina Ziehn²

Introduction

Ø

- Microglia are innate immune cells of CNS and their overactivation has been implicated in the pathogenesis of MS¹
- B-cell depletion using anti-CD20 antibodies led to reduced microglial activation and lesion formation in animal models²
- An 18-kilodalton translocator protein (TSPO) is over expressed on the outer mitochondrial membrane of activated microglia.

A quantitative TSPO positron emission tomography (PET) with a second-generation 18F-PBR06 ligand has been used to assess the microglial activation in patients with MS³

- Of a fully human anti-CD20 monoclonal antibody approved for the treatment of RMS in adults in the US, Europe and other countries*
- The potential impact of of atumumab on microglial activation in MS is currently unknown

To determine the effect of ofatumumab on microglial activation in relation to changes in serum markers, MRI abnormalities and clinical impairment longitudinally over 9 months using [F-18]PBR06-Objective **PET in RMS patients**


*Australia, Canada, Singapore, Switzerland, UAE, Albania, Argentina, India, Japan, Great Britain and Brazil. CNS, central nervous system; MS, multiple sclerosis;; RMS, relapsing multiple sclerosis. 1. Olcum M, et al. Adv Protein Chem Struct Biol. 2020;119:247-308. 2. Anthony DC, et al. Ann Clin Transl Neurol. 2014;1:659-669. 3. Singhal T, et al. Neurol Neuroinflamm. 2019;6:e587.



#EPR-225

Study design

An open-label, single center, observational, prospective, 9-month study in RMS patients



MRI, magnetic resonance imaging; OMB, ofatumumab; PET, positron emission tomography; RMS, relapsing multiple sclerosis

Study Eligibility criteria

Key inclusion criteria

- RMS patients aged 18 to 60 years
- Diagnosed with active^a, relapsing MS course¹
- EDSS 0 to 5.5
- Normal CD19 (>110/µL), WBC (>4000/µL), lymphocytes (>1000/µL) and IgG level (>700mg/dL)
- Variable transition time from other DMTs





Key exclusion criteria

- Subjects suspected of not being able or willing to cooperate or comply with study protocol requirements in the opinion of the investigator
- Subjects with primary progressive MS² or SPMS without disease activity¹
- Disease duration of more than 10 years in patients with an EDSS score of 2 or less
- Subjects with low TSPO binding affinity

^aat least 1 relapse during the previous 1 year or 2 relapses during the previous 2 years or a positive gadolinium-enhancing MRI scan or MRI scan with new or unequivocally enlarging T2 lesions in previous year DMTs, disease-modifying therapies; EDSS, Expanded Disability Status Scale; Ig, immunoglobulin; RMS, relapsing multiple sclerosis; SPMS, secondary progressive multiple sclerosis 1. Lublin FD, et al. *Neurology*. 2014;83(3):278-286. Polman CH, et al. *Annals of neurology*. 2011;69:292-302.

Study objectives and endpoints

Primary

 To determine the effect of ofatumumab on microglial activation over 9 months in patients with RMS



- To determine the time course of effect of ofatumumab on microglial activation and its relationship at Days 5, 28, 90 and 273 with:
 - Peripheral B-cell depletion
 - Serum neurofilament light chain
 - Glial-fibrillary acid protein levels
 - Other serum biomarkers (IP-10, ITAC, MCP-1 and MIP-3b)
- To determine the relationship of PET changes following ofatumumab initiation with 3T MRI changes (including QSM) and clinical parameters (EDSS, T25FW, MFIS, relapses)

Conclusions

- ✓ This is the first study to evaluate the effect of ofatumumab on microglial activation and its relationship with serum markers of neurodegeneration
- ✓ This study will also assess the relationship between peripheral B-cell depletion and changes in microglial activation following of atumumab administration
- ✓ Patient enrollment is expected to complete by the end of 2021

Disclosures

Tarun Singhal has received compensation for consulting from Novartis. He has received research support from National MS Society, US Department of Defense, Nancy Davis Foundation's "Race to Erase MS" program, Harvard Neuro-Discovery Center, Novartis Pharmaceuticals and Sanofi Genzyme. Howard L Weiner has received compensation for consulting from Tiziana Life Sciences and vTv Therapeutics. He has received research support from the Cure Alzheimer's Fund, Department of Defense, Genentech, Inc., National Institutes of Health, National Multiple Sclerosis Society, Novartis and Sanofi Genzyme. He has stock options with vTv Therapeutics. Tanuja Chitnis has received compensation for consulting from Biogen, Novartis Pharmaceuticals, Roche Genentech, and Sanofi Genzyme. She has received research support from the National Institutes of Health, National MS Society, US Department of Defense, Sumaira Foundation, Brainstorm Cell Therapeutics, EMD Serono, I-Mab Biopharma, Mallinckrodt ARD, Novartis Pharmaceuticals, Octave Bioscience, Roche Genentech, and Tiziana Life Sciences. Disclosures do not conflict with the work being presented. Rohit Bakshi has received consulting fees from EMD Serono and research support from BMS/Celgene, EMD Serono, and Novartis. Maria Houtchens has received consulting fees from Biogen, Kelsey O'Connor, John Hunter Ficke, Eero Rissanen, Steven Cicero and Jon Zurawski have nothing to disclose. Nicholas Seneca was an employee of Novartis at the time of study design. Harald Kropshofer, Brandon Brown and Marina Ziehn are employees of Novartis.

Affiliations

¹Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ²Novartis Pharma AG, Basel, Switzerland; ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA